eMedicine Specialties > Pediatrics: General Medicine > Parasitology

Isosporiasis: Differential Diagnoses & Workup

Author: Robert W Tolan Jr, MD, Chief, Division of Allergy, Immunology and Infectious Diseases, The Children's Hospital at Saint Peter's University Hospital; Clinical Associate Professor of Pediatrics, Drexel University College of Medicine
Contributor Information and Disclosures

Updated: Jan 22, 2009

Differential Diagnoses

Amebiasis
Hemolytic-Uremic Syndrome
Ancylostoma Infection
Hepatitis A
Appendicitis
Hookworm Infection
Ascariasis
Hymenolepiasis
Atypical Mycobacterial Infection
Intestinal Enterokinase Deficiency
Campylobacter Infections
Intestinal Malrotation
Cholera
Intestinal Protozoal Diseases
Colic
Intestinal Volvulus
Colitis
Intussusception
Constipation
Irritable Bowel Syndrome
Cryptosporidiosis
Lactose Intolerance
Cyclosporiasis
Malabsorption Syndromes
Cytomegalovirus Infection
Peptic Ulcer Disease
Dehydration
Protein-Losing Enteropathy
Diarrhea
Salmonella Infection
Dientamoeba Fragilis Infection
Shigella Infection
Diphyllobothrium Latum Infection
Short Bowel Syndrome
Echovirus
Small-Bowel Obstruction
Enterobiasis
Soy Protein Intolerance
Enteroviral Infections
Sprue
Escherichia Coli Infections
Strongyloidiasis
Fascioliasis
Ulcerative Colitis
Food Poisoning
Volvulus
Gastroenteritis
Whipworm
Giardiasis

Other Problems to Be Considered

Aeromonas infection
Clostridium difficile infection
Celiac disease
Kaposi sarcoma
Lymphoma
Microsporidiosis
Sarcocystis infection

Workup

Laboratory Studies

  • Stool examination for ova and parasites is the test of choice for isosporiasis.
    • Mature oocysts measure 30 X 12 µm and have a thin translucent wall and 2 round sporocysts, each of which has 4 crescentic sporozoites.
    • Auramine-rhodamine fluorescent, modified Kinyoun acid-fast, hematoxylin/eosin, Giemsa, and/or carbol fuchsin staining may be helpful in identifying the translucent oocysts.
    • Oocysts autofluoresce under ultraviolet epifluorescence illumination using a 450- to 490-nm excitation filter.
    • Charcot-Leyden crystals and high fat content are often observed.
  • CBC count may reveal mild peripheral eosinophilia in one half of patients.
  • Serologic testing is not available.
  • Electron microscopy may be helpful, but it is labor intensive and lacks specificity.

Imaging Studies

Double contrast barium upper GI series with small-bowel follow-through may be helpful.

  • The severity of radiographic findings seems to depend on duration of illness and to correlate with the degree of villous atrophy noted on biopsy findings.
  • Short-term disease (<1 y) seems to result in minimal or irregular thickening of mucosal folds.
  • Long-term disease seems to correlate with markedly granular mucosal appearance with effacement of the folds.

Other Tests

  • The Entero-Test (swallowed string test to provide a duodenal sample) may yield a positive specimen, if stool study results are negative.

Procedures

Upper GI endoscopy may provide useful specimens for examination, if the following test results are negative:

  • Duodenal aspirate for ova and parasite examination
  • Small bowel biopsy for histopathology

Histologic Findings

  • Histologic findings appear to correlate with the severity of the symptoms observed. Focal-to-widespread mucosal changes are associated with severe symptoms.
  • In mild cases, the only findings may range from flattened villi to mild, nonspecific alterations and increased inflammatory cells in the lamina propria.

More on Isosporiasis

Overview: Isosporiasis
Differential Diagnoses & Workup: Isosporiasis
Treatment & Medication: Isosporiasis
Follow-up: Isosporiasis
References

References

  1. Sorvillo FJ, Lieb LE, Seidel J, et al. Epidemiology of isosporiasis among persons with acquired immunodeficiency syndrome in Los Angeles County. Am J Trop Med Hyg. Dec 1995;53(6):656-9. [Medline].

  2. DeHovitz JA, Pape JW, Boncy M, Johnson WD Jr. Clinical manifestations and therapy of Isospora belli infection in patients with the acquired immunodeficiency syndrome. N Engl J Med. Jul 10 1986;315(2):87-90. [Medline].

  3. Limson-Pobre RN, Merrick S, Gruen D, Soave R. Use of diclazuril for the treatment of isosporiasis in patients with AIDS. Clin Infect Dis. Jan 1995;20(1):201-2. [Medline].

  4. Fox LM, Saravolatz LD. Nitazoxanide: a new thiazolide antiparasitic agent. Clin Infect Dis. Apr 15 2005;40(8):1173-80. [Medline].

  5. Gilles HM, Hoffman PS. Treatment of intestinal parasitic infections: a review of nitazoxanide. Trends Parasitol. Mar 2002;18(3):95-7. [Medline].

  6. AAP. Isosporiasis. In: Red Book: Report of the Committee on Infectious Diseases. American Academy of Pediatrics; 2006:411-2, 800.

  7. Ackers JP. Gut Coccidia--Isospora, Cryptosporidium, Cyclospora and Sarcocystis. Semin Gastrointest Dis. Jan 1997;8(1):33-44. [Medline].

  8. Atambay M, Bayraktar MR, Kayabas U, Yilmaz S, Bayindir Y. A rare diarrheic parasite in a liver transplant patient: Isospora belli. Transplant Proc. Jun 2007;39(5):1693-5. [Medline].

  9. Behera B, Mirdha BR, Makharia GK, Bhatnagar S, Dattagupta S, Samantaray JC. Parasites in patients with malabsorption syndrome: a clinical study in children and adults. Dig Dis Sci. Mar 2008;53(3):672-9. [Medline].

  10. Benson CA, Kaplan JE, Masur H, et al. Treating opportunistic infections among HIV-exposed and infected children: recommendations from CDC, the National Institutes of Health, and the Infectious Diseases Society of America. MMWR Recomm Rep. Dec 17 2004;53(RR-15):1-112. [Medline].

  11. Dwivedi KK, Prasad G, Saini S, Mahajan S, Lal S, Baveja UK. Enteric opportunistic parasites among HIV infected individuals: associated risk factors and immune status. Jpn J Infect Dis. May 2007;60(2-3):76-81. [Medline].

  12. Farthing MJ. Treatment options for the eradication of intestinal protozoa. Nat Clin Pract Gastroenterol Hepatol. Aug 2006;3(8):436-45. [Medline][Full Text].

  13. Guiguet M, Furco A, Tattevin P, Costagliola D, Molina JM,. HIV-associated Isospora belli infection: incidence and risk factors in the French Hospital Database on HIV. HIV Med. Mar 2007;8(2):124-30. [Medline].

  14. Heyworth MF. Parasitic diseases in immunocompromised hosts. Cryptosporidiosis, isosporiasis, and strongyloidiasis. Gastroenterol Clin North Am. Sep 1996;25(3):691-707. [Medline].

  15. Hizawa K, Iida M, Eguchi K, et al. Comparative features of double-contrast barium studies in patients with isosporiasis and strongyloidiasis. Clin Radiol. Oct 1998;53(10):764-7. [Medline].

  16. Jongwutiwes S, Putaporntip C, Charoenkorn M, Iwasaki T, Endo T. Morphologic and molecular characterization of Isospora belli oocysts from patients in Thailand. Am J Trop Med Hyg. Jul 2007;77(1):107-12. [Medline].

  17. Karanis P, Kourenti C, Smith H. Waterborne transmission of protozoan parasites: a worldwide review of outbreaks and lessons learnt. J Water Health. Mar 2007;5(1):1-38. [Medline].

  18. Kochhar A, Saxena S, Malhotra VL, Deb M. Isospora belli infection in a malnourished child. J Commun Dis. Jun 2007;39(2):141-3. [Medline].

  19. Lewthwaite P, Gill GV, Hart CA, Beeching NJ. Gastrointestinal parasites in the immunocompromised. Curr Opin Infect Dis. Oct 2005;18(5):427-35. [Medline].

  20. Lindsay DS, Dubey JP, Blagburn BL. Biology of Isospora spp. from humans, nonhuman primates, and domestic animals. Clin Microbiol Rev. Jan 1997;10(1):19-34. [Medline][Full Text].

  21. Mannheimer SB, Soave R. Protozoal infections in patients with AIDS. Cryptosporidiosis, isosporiasis, cyclosporiasis, and microsporidiosis. Infect Dis Clin North Am. Jun 1994;8(2):483-98. [Medline].

  22. Marshall MM, Naumovitz D, Ortega Y, Sterling CR. Waterborne protozoan pathogens. Clin Microbiol Rev. Jan 1997;10(1):67-85. [Medline][Full Text].

  23. Pape JW, Verdier RI, Boncy M. Cyclospora infection in adults infected with HIV. Clinical manifestations, treatment, and prophylaxis. Ann Intern Med. Nov 1 1994;121(9):654-7. [Medline][Full Text].

  24. Pape JW, Verdier RI, Johnson WD Jr. Treatment and prophylaxis of Isospora belli infection in patients with the acquired immunodeficiency syndrome. N Engl J Med. Apr 20 1989;320(16):1044-7. [Medline].

  25. Pickering LK. Therapy for acute infectious diarrhea in children. J Pediatr. Apr 1991;118(4 ( Pt 2)):S118-28. [Medline].

  26. Ribes JA, Seabolt JP, Overman SB. Point prevalence of Cryptosporidium, Cyclospora, and Isospora infections in patients being evaluated for diarrhea. Am J Clin Pathol. Jul 2004;122(1):28-32. [Medline].

  27. Robertson J, Shilkofski N. Drug doses. In: The Harriet Lane Handbook: A Manual for Pediatric House Officers. Philadelphia, Pa: Mosby; 2005:679-1009.

  28. Soave R. Cryptosporidiosis and isosporiasis in patients with AIDS. Infect Dis Clin North Am. Jun 1988;2(2):485-93. [Medline].

  29. Sun T. Current topics in protozoal diseases. Am J Clin Pathol. Jul 1994;102(1):16-29. [Medline].

  30. ten Hove RJ, van Lieshout L, Brienen EA, Perez MA, Verweij JJ. Real-time polymerase chain reaction for detection of Isospora belli in stool samples. Diagn Microbiol Infect Dis. Jul 2008;61(3):280-3. [Medline].

  31. Thielman NM, Guerrant RL. Persistent diarrhea in the returned traveler. Infect Dis Clin North Am. Jun 1998;12(2):489-501. [Medline].

  32. Valentiner-Branth P, Steinsland H, Fischer TK, et al. Cohort study of Guinean children: incidence, pathogenicity, conferred protection, and attributable risk for enteropathogens during the first 2 years of life. J Clin Microbiol. Sep 2003;41(9):4238-45. [Medline][Full Text].

  33. Verdier RI, Fitzgerald DW, Johnson WD Jr, Pape JW. Trimethoprim-sulfamethoxazole compared with ciprofloxacin for treatment and prophylaxis of Isospora belli and Cyclospora cayetanensis infection in HIV-infected patients. A randomized, controlled trial. Ann Intern Med. Jun 6 2000;132(11):885-8. [Medline][Full Text].

  34. Weiss LM, Keohane EM. The uncommon gastrointestinal Protozoa: Microsporidia, Blastocystis, Isospora, Dientamoeba, and Balantidium. Curr Clin Top Infect Dis. 1997;17:147-87. [Medline].

  35. Weiss LM, Perlman DC, Sherman J, et al. Isospora belli infection: treatment with pyrimethamine. Ann Intern Med. Sep 15 1988;109(6):474-5. [Medline].

  36. Wiesner J, Reichenberg A, Heinrich S, Schlitzer M, Jomaa H. The plastid-like organelle of apicomplexan parasites as drug target. Curr Pharm Des. 2008;14(9):855-71. [Medline].

  37. Wittner M, Tanowitz HB, Weiss LM. Parasitic infections in AIDS patients. Cryptosporidiosis, isosporiasis, microsporidiosis, cyclosporiasis. Infect Dis Clin North Am. Sep 1993;7(3):569-86. [Medline].

Further Reading

Keywords

isosporiasis, Apicomplexa coccidia protozoan, dehydration, diarrhea, foul-smelling flatus, gastrointestinal infection, GI infection, Isospora, Isospora belli, I belli, I belli disease, I belli infection, parasitic infection, steatorrhea

Contributor Information and Disclosures

Author

Robert W Tolan Jr, MD, Chief, Division of Allergy, Immunology and Infectious Diseases, The Children's Hospital at Saint Peter's University Hospital; Clinical Associate Professor of Pediatrics, Drexel University College of Medicine
Robert W Tolan Jr, MD is a member of the following medical societies: American Academy of Pediatrics, American Medical Association, American Society for Microbiology, American Society of Tropical Medicine and Hygiene, Infectious Diseases Society of America, Pediatric Infectious Diseases Society, Phi Beta Kappa, and Physicians for Social Responsibility
Disclosure: GlaxoSmithKline Honoraria Speaking and teaching; MedImmune Honoraria Consulting; MedImmune Honoraria Speaking and teaching; Merck Honoraria Speaking and teaching; Novartis Honoraria Speaking and teaching; sanofi pasteur Grant/research funds Unrestricted research grant; sanofi pasteur  Consulting; sanofi pasteur Honoraria Speaking and teaching; Tap Honoraria Speaking and teaching; Baxter Healthcare Honoraria Speaking and teaching

Medical Editor

Glenn J Fennelly, MD, MPH, Director, Division of Pediatric Infectious Diseases, Jacobi Medical Center; Associate Professor, Department of Pediatrics, Albert Einstein College of Medicine
Glenn J Fennelly, MD, MPH is a member of the following medical societies: Pediatric Infectious Diseases Society
Disclosure: Nothing to disclose.

Pharmacy Editor

Mary L Windle, PharmD, Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy, Pharmacy Editor, eMedicine
Disclosure: Pfizer Inc Stock Investment from financial planner; Avanir Pharma Stock Investment from financial planner ; WebMD Salary and stock Employment and investment from financial planner

Managing Editor

Martin Weisse, MD, Program Director, Associate Professor, Department of Pediatrics, West Virginia University
Martin Weisse, MD is a member of the following medical societies: Ambulatory Pediatric Association, American Academy of Pediatrics, and Pediatric Infectious Diseases Society
Disclosure: Nothing to disclose.

CME Editor

Daniel Rauch, MD, FAAP, Director, Pediatric Hospitalist Program, Associate Professor, Department of Pediatrics, New York University School of Medicine
Daniel Rauch, MD, FAAP is a member of the following medical societies: Ambulatory Pediatric Association, American Academy of Pediatrics, and Society of Hospital Medicine
Disclosure: Baxter Honoraria Consulting; Pfizer Honoraria Consulting

Chief Editor

Russell W Steele, MD, Head, Division of Pediatric Infectious Diseases, Ochsner Children's Health Center; Clinical Professor, Department of Pediatrics, Tulane University School of Medicine
Russell W Steele, MD is a member of the following medical societies: American Academy of Pediatrics, American Association of Immunologists, American Pediatric Society, American Society for Microbiology, Infectious Diseases Society of America, Louisiana State Medical Society, Pediatric Infectious Diseases Society, Society for Pediatric Research, and Southern Medical Association
Disclosure: None None None

RELATED EMEDICINE ARTICLES
 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.